06/24/2020 12:00 AM EDT
Source: U.S. Senate, Committee on Homeland Security and Governmental Affairs. Published: 6/24/2020. This Congressional hearing features witnesses who discuss the mission of the Strategic National Stockpile, maintenance of its inventory, and effective management of its relationships with industry and state, local, tribal, and territorial authorities. They discuss its role in the COVID-19 pandemic, and provide recommendations for rethinking the national stockpiling capabilities for future biological events, including pandemics. (Video or Multimedia)
06/23/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/23/2020. This web page provides information about a webinar discussing the importation of respirators, and the Food and Drug Administration's collaboration with the Centers for Disease Control and Prevention on the sampling and testing of international respirators in support of the FDA's respirator Emergency Use Authorizations. It also describes respirator testing, including the modified filtration efficiency testing the National Institute for Occupational Safety and Health (NIOSH) completes as part of its international respirator assessments. It is part of a webinar series on Respirators for Health Care Personnel Use During COVID-19 Pandemic. (Text)
06/23/2020 12:00 AM EDT
Source: U.S. House of Representatives, Committee on Energy and Commerce. Published: 6/23/2020. This five-hour, 50-minute Congressional hearing features public health officials who discuss the U.S. response to the COVID-19 pandemic, and how to prepare to combat the disease as more outbreaks flare up this summer and a potential second wave comes in the fall. The witnesses answer questions about what has gone wrong, what is improving, and how to prepare going forward. (Video or Multimedia)
06/23/2020 12:00 AM EDT
Source: U.S. House of Representatives, Committee on Science, Space, and Technology. Published: 6/23/2020. This one-hour, 41-minute Congressional hearing focuses on the role of R&D in understanding and mitigating the risk of COVID-19 transmission through air travel, and features witnesses who discuss how the research is being translated to operational solutions for the airlines, crew, and the flying public. (Video or Multimedia)
06/19/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/19/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold). The LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold) is authorized for the detection of IgG and IgM antibodies to SARS-CoV-2 in human serum and plasma (dipotassium-EDTA, lithium-heparin, or sodium-citrate). (PDF)
06/19/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/19/2020. This Food and Drug Administration (FDA) letter recommends that clinical laboratories and health care providers stop using COVID-19 antibody tests that are listed on FDA’s “removed” test list. The “removed” test list includes tests where significant clinical performance problems were identified that cannot be or have not been addressed by the commercial manufacturer in a timely manner, tests for which an Emergency Use Authorization request has not been submitted by a commercial manufacturer of a serology test within a reasonable period of time as outlined in FDA’s guidance, and tests voluntarily withdrawn by the respective commercial manufacturers. (Text)
06/19/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/19/2020. This web page provides information on the use of non-contact temperature assessment devices during the COVID-19 pandemic, including benefits, limitations, and regulations. (Text)
06/19/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/19/2020. This web page provides fact sheets, newsletters, and links to a zip file of documents about convalescent plasma for health professionals, as part of the development of numerous potential COVID-19 treatments. (Text)
06/19/2020 12:00 AM EDT
Source: U.S. House of Representatives, Committee on Science, Space, and Technology. Published: 6/19/2020. This one-hour, 27-minute Congressional hearing revolves around one of the most promising tools in the public health response to the COVID-19 pandemic: repurposing existing therapeutic drugs to treat COVID-19. In the absence of any COVID-19 vaccine or novel treatment, existing therapeutics could potentially offer critical assistance for severely ill patients and bridge the gap until more prevention and treatment options become available. (Video or Multimedia)
06/17/2020 12:00 AM EDT
Source: U.S. House of Representatives, Committee on Energy and Commerce. Published: 6/17/2020. This three-hour, 51-minute Congressional hearing discusses the racial and ethnic disparities in the COVID-19 pandemic, as well as the inequities within the larger health care system. It features witnesses who share their expertise about the factors that have left minority communities especially vulnerable to the COVID-19 pandemic. (Video or Multimedia)
06/09/2020 12:00 AM EDT
Source: U.S. House of Representatives, Committee on Energy and Commerce. Published: 6/9/2020. This three-hour, 12-minute Congressional hearing discusses the COVID-19 pandemic's disproportionate impact on environmental justice communities, and the high rates of infection and death for communities of color, low-income communities, Native American communities, and fence-line communities, such as communities that are adjacent to chemical plants or Superfund sites. (Video or Multimedia)
06/09/2020 12:00 AM EDT
Source: U.S. Senate, Committee on Homeland Security and Governmental Affairs. Published: 6/9/2020. The focus of this two-hour, 30-minute Congressional hearing is to understand how the federal government has reacted to the challenges in procuring and distributing critical medical equipment and supplies during the COVID-19 pandemic, and begin to evaluate what may be necessary to ensure we are better prepared in the future. (Video or Multimedia)
06/03/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/3/2020. This 22-page resource is intended for labs performing COVID-19 tests that are authorized. It includes validated supply alternatives that labs can use to continue performing testing when there is a supply issue with some components of a test. (PDF)
No hay comentarios:
Publicar un comentario